Clinical and Translational Oncology

, Volume 20, Issue 2, pp 201–211 | Cite as

Cancer survival in adult patients in Spain. Results from nine population-based cancer registries

  • M. D. ChirlaqueEmail author
  • D. Salmerón
  • J. Galceran
  • A. Ameijide
  • A. Mateos
  • A. Torrella
  • R. Jiménez
  • N. Larrañaga
  • R. Marcos-Gragera
  • E. Ardanaz
  • M. Sant
  • P. Minicozzi
  • C. Navarro
  • M. J. Sánchez
  • the REDECAN Working Group
Research Article



With the aim of providing cancer control indicators, this work presents cancer survival in adult (≥15 years) patients in Spain diagnosed during the period 2000–2007 from Spanish cancer registries participating in the EUROCARE project.


Cancer cases from nine Spanish population-based cancer registries were included and analysed as a whole. All primary malignant neoplasms diagnosed in adult patients were eligible for the analysis. Cancer patients were followed until 31 December 2008. For each type of cancer, 1-, 3- and 5-year observed and relative survival were estimated by sex, age and years from diagnosis. Furthermore, age-standardized 5-year relative survival for the period 2000–2007 has been compared with that of the period 1995–1999.


Skin melanoma (84.6 95% CI 83.0–86.2), prostate (84.6% 95% CI 83.6–85.6) and thyroid (84.2% CI 95% 82.0–86.6) cancers showed the highest 5-year relative survival, whereas the worst prognosis was observed in pancreatic (6% 95% CI 5.1–7.0) and oesophageal (9.4% 95% CI 7.9–11.1) cancers. Overall, survival is higher in women (58.0%) than in men (48.9%). The absolute difference in relative survival between 2000–2007 and 1995–1999 was positive for all cancers as a whole (+4.8% in men, +1.6% in women) and for most types of tumours. Survival increased significantly for chronic myeloid leukaemia, non-Hodgkin’s lymphoma and rectum cancer in both sexes, and for acute lymphoid leukaemia, prostate, liver and colon cancers in men and Hodgkin’s lymphoma and breast cancer in women. Survival patterns by age were similar in Europe and Spain. A decline in survival by age was observed in all tumours, being more pronounced for ovarian, corpus uteri, prostate and urinary bladder and less for head and neck and rectum cancers.


High variability and differences have been observed in survival among adults in Spain according to the type of cancer diagnosed, from above 84% to below 10%, reflecting high heterogeneity. The differences in prognosis by age, sex and period of diagnosis reveal opportunities for improving cancer care in Spain.


Cancer Survival Cancer registries Prognosis Population-based Spain 



Compagnia Intesa San Paolo (Grant No. 2010.1354) and the Fondazione Cariplo (Grant No. 2010.1984).

REDECAN Working Group: Albacete (Antonio Mateos, Enrique Almar), Asturias (José Ramón Quirós, Marcial V. Argüelles, Virginia Menéndez), Canarias (Dolores Rojas, Araceli Alemán), Castellón (Ana Torrella, Consol Sabater, Paloma Botella), Ciudad Real (Matilde Chico, María Ripoll, Cristina Díaz), Infantil de la Comunitat Valenciana (Marisa Vicente, Nieves Fuster, Paloma Botella), Cuenca (José María Díaz, Rosario Jiménez, Ana Isabel Marcos Navarro), Euskadi-Basque Country (Nerea Larrañaga, Joseba Bidaurrazaga, Arantza Lopez-de-Munain), Girona (Rafael Marcos-Gragera, Àngel Izquierdo, Loreto Vilardell), Granada (María José Sánchez, Elena Molina-Portillo, Miguel Rodríguez-Barranco), La Rioja (Josefina Perucha), Mallorca (Paula Franch, Maria Ramos), Murcia (Carmen Navarro, María Dolores Chirlaque, Diego Salmerón), Navarra (Eva Ardanaz, Marcela Guevara, Rosana Burgui), Tarragona (Jaume Galceran, Alberto Ameijide, Marià Carulla, Jàmnica Bigorra), Registro Español de Tumores Infantiles (Rafael Peris Bonet, Elena Pardo).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This work does not contain clinical studies or patient data.

Informed consent

For this type of study formal consent is not required.

Supplementary material

12094_2017_1710_MOESM1_ESM.xls (32 kb)
Supplementary material 1 (XLS 32 kb)


  1. 1.
    Navarro C, Martos C, Ardanaz E, Galceran J, Izarzugaza I, Peris-Bonet R, Spanish Cancer Registries Working Group, et al. Population-based cancer registries in Spain and their role in cancer control. Ann Oncol. 2010;21(Suppl 3):iii3–13.PubMedGoogle Scholar
  2. 2.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014;15(1):23–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Francisci S, Minicozzi P, Pierannunzio D, Ardanaz E, Eberle A, Grimsrud TK, et al. Survival patterns in lung and pleural cancer in Europe 1999–2007: results from the EUROCARE-5 study. Eur J Cancer. 2015;51:2242–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51:2191–205.CrossRefPubMedGoogle Scholar
  5. 5.
    Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, et al. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: results of EUROCARE-5. Eur J Cancer. 2015;51:2169–78.CrossRefPubMedGoogle Scholar
  6. 6.
    Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.CrossRefPubMedGoogle Scholar
  7. 7.
    Marcos-Gragera R, Salmerón D, Izarzugaza I, Ardanaz E, Serdà BC, Larrañaga N, et al. Trends in prostate cancer survival in Spain: results from population-based cancer registries. Clin Transl Oncol. 2012;14(6):458–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Salmerón D, Chirlaque MD, Isabel Izarzugaza M, Sánchez MJ, Marcos-Gragera R, Ardanaz E, et al. Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 2012;106(9):1301–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Chirlaque MD, Salmerón D, Ardanaz E, Galceran J, Martínez R, Marcos-Gragera R, et al. Cancer survival in Spain: estimate for nine major cancers. Ann Oncol. 2010;21(Suppl 3):iii21–9.PubMedGoogle Scholar
  10. 10. Accessed 2 Jun 2017.
  11. 11. Accessed 2 Jun 2017.
  12. 12.
    Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer. 2009;45(6):931–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al. editors. Cancer incidence in five continents, vol. X. IARC scientific publication no. 164. Lyon: International Agency for Research on Cancer; 2014.Google Scholar
  14. 14.
    Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P, EUROCARE-5 Working Group, et al. The EUROCARE-5 study on cancer survival in Europe 1999–2007: database, quality checks and statistical analysis methods. Eur J Cancer. 2015;51:2104–19.CrossRefPubMedGoogle Scholar
  15. 15.
    Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin M, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization. 2000.Google Scholar
  16. 16.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.Google Scholar
  17. 17.
    IACR-ENCR. International rules for multiple primary cancers (ICD-O 3rd ed). Lyon: IACR; 2004. Accessed 2 Jun 2017.
  18. 18.
    Spanish Data Protection Agency. (2004). Accessed 2 Jun 2017.
  19. 19.
    European Network of Cancer Registries. Guidelines on confidentiality in population-based Cancer Registration in the European Union. Lyon: ENCR; 2002.Google Scholar
  20. 20.
    Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. End results evaluation section. National Cancer Institute: Bethseda; 1959.Google Scholar
  21. 21.
    Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40(15):2307–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38:933–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Parkin DM, Hakulinen T. Cancer registration: principles and methods. Analysis of survival. IARC Sci Publ. 1991;95:159–76.Google Scholar
  24. 24.
    Crocetti E, Mallone S, Robsahm TE, Gavin A, Agius D, Ardanaz E, EUROCARE Working Group, et al. Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer. 2015;51:2179–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Lyth J, Mikiver R, Nielsen K, Isaksson K, Ingcar C. Prognostic instrument for survival outcome in melanoma patients: base on data from the population-based Swedish Melanoma Register. Eur J Cancer. 2016;59:171–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Crocetti E, Fancelli L, Manneschi G, Caldarella A, Pimpinelli N, Chiarugi A, et al. Melanoma survival: sex does matter, but we do not known how. Eur J cáncer Prev. 2016;25(5):404–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P. Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. J Am Acad Dermatol. 2016;75(5):967–74.CrossRefPubMedGoogle Scholar
  28. 28.
    Nosrati A, Wei ML. Sex disparities in melanoma outcomes: the role of biology. Arch Biochem Biophys. 2014;563:42–50.CrossRefPubMedGoogle Scholar
  29. 29.
    Chirlaque MD, Moldenhauer F, Salmerón D, Navarro C. Trends pattern of the incidence of thyroid cancer in Murcia Region (Spain) from 1984 to 2008. Gac Sanit. 2014;28(5):397–400.CrossRefPubMedGoogle Scholar
  30. 30.
    Leboulleux S, Tuttle RM, Pacini F, Schlumberger M. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 2016;4:933–42.CrossRefPubMedGoogle Scholar
  31. 31.
    Akhtar-Danesh GG, Finley C, Akhtar-Danesh N. Long-term trends in the incidence and relative survival of pancreatic cancer in Canada: a population-based study. Pancreatology. 2016;16(2):259–65.CrossRefPubMedGoogle Scholar
  32. 32.
    Romiti A, Falcone R, Roberto M, Marchetti P. Tackling pancreatic cancer with metronomic chemotherapy. Cancer Lett. 2017;394:88–95.Google Scholar
  33. 33.
    Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY, Wang L, et al. Early detection of pancreatic cancer: where are we now and where are we going? Int J Cancer. 2017;141:231–41.CrossRefPubMedGoogle Scholar
  34. 34.
    Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L, the EUROCARE Working Group. Prognoses and improvement for head and neck cancers diagnosed in Europe in early: the EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2130–43.Google Scholar
  35. 35.
    Guizard AV, Uhry Z, de Raucourt D, Mazzoleni G, Sánchez MJ, Ligier K, GRELL EUROCARE-5 Working Group. Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S16–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Anderson LA, Tavilla A, Brenner H, Luttmann S, Navarro C, Gavin AT, EUROCARE-5 Working Group, et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999–2007: results from EUROCARE-5. Eur J Cancer. 2015;51:2144–57.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Holleczek B, Rossi S, Domenic A, Innos K, Minicozzi P, Francisci S, EUROCARE-5 Working Group, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007—results from the EUROCARE-5 study. Eur J Cancer. 2015;51:2158–68.CrossRefPubMedGoogle Scholar
  38. 38.
    Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.CrossRefPubMedGoogle Scholar
  39. 39.
    Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, EUROCARE-5 Working Group, et al. Urinary tract cancer survival in Europe 1999–2007: results of the population-based study EUROCARE-5. Eur J Cancer. 2015;51:2217–30.CrossRefPubMedGoogle Scholar
  40. 40.
    Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P, EUROCARE-5 Working Group. Survival of adults with primary malignant brain tumours in Europe; results of the EUROCARE-5 study. Eur J Cancer. 2015;51:2231–41.CrossRefPubMedGoogle Scholar
  41. 41.
    Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-Raspall R, Serraino D, EUROCARE-5 Working Group, et al. Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: results from the EUROCARE-5 study. Eur J Cancer. 2015;51:2206–16.CrossRefPubMedGoogle Scholar
  42. 42.
    Campá J, Mar-Barrutia G, Extramiana J, Arróspide A, Mar J. Advanced prostate cancer survival in Spain according to the Gleason score, age and stage. Actas Urol Esp. 2016;40(8):499–506.CrossRefPubMedGoogle Scholar
  43. 43.
    De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Belot A, et al. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer. 2009;45(6):909–30.CrossRefPubMedGoogle Scholar
  44. 44.
    De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, EUROCARE-5 Working Group, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: results of EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2254–68.CrossRefPubMedGoogle Scholar
  45. 45.
    Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Guàrdia R, et al. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study. Leuk Lymphoma. 2015;56(4):896–902.CrossRefPubMedGoogle Scholar
  46. 46.
    Ellison LF. Differences in cancer survival in Canada by sex. Health Rep. 2016;27(4):19–27.Google Scholar
  47. 47.
    Oberaigner W, Siebert U. Do women with cancer have better survival as compared to men after adjusting for staging distribution? Eur J Public Health. 2011;21(3):387–91.CrossRefPubMedGoogle Scholar
  48. 48.
    Baili P, Di Salvo F, Marcos-Gragera R, Siesling S, Mallone S, Santaquilani M, et al. Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: results of EUROCARE-5, a population-based study. Eur J Cancer. 2015;51:2120–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017–27.CrossRefPubMedGoogle Scholar
  50. 50.
    Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E, EUROCARE Working Group, et al. Multiple tumours in survival estimates. Eur J Cancer. 2009;45(6):1080–94.CrossRefPubMedGoogle Scholar
  51. 51.
    Rutherford MJ, Dickman PW, Lambert PC. Comparison of methods for calculating relative survival in population-based studies. Cancer Epidemiol. 2012;36(1):16–21.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  • M. D. Chirlaque
    • 1
    • 2
    Email author
  • D. Salmerón
    • 1
    • 2
  • J. Galceran
    • 3
  • A. Ameijide
    • 3
  • A. Mateos
    • 4
  • A. Torrella
    • 5
  • R. Jiménez
    • 6
  • N. Larrañaga
    • 2
    • 7
  • R. Marcos-Gragera
    • 8
  • E. Ardanaz
    • 2
    • 9
  • M. Sant
    • 10
  • P. Minicozzi
    • 10
  • C. Navarro
    • 1
    • 2
  • M. J. Sánchez
    • 2
    • 11
  • the REDECAN Working Group
  1. 1.Department of Epidemiology, Regional Health Authority, IMIB-ArrixacaMurcia UniversityMurciaSpain
  2. 2.CIBER in Epidemiology and Public Health (CIBERESP)MadridSpain
  3. 3.Tarragona Cancer Registry, Foundation Society for Cancer Research and Prevention, Pere Virgili Health Research InstituteReusSpain
  4. 4.Albacete Cancer Registry, Health and Social Welfare AuthorityCastile-La ManchaSpain
  5. 5.Castellón Cancer Registry, Public Health Directorate, Valencian GovernmentCastellónSpain
  6. 6.Cuenca Cancer Registry, Health and Social Welfare AuthorityCastile-La ManchaSpain
  7. 7.Basque Country Cancer Registry, Basque Country Regional AuthorityVitoria-GasteizSpain
  8. 8.Epidemiology Unit and Girona Cancer Registry (UERCG), Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona Biomedical Institute (IDIBGI)University of GironaGironaSpain
  9. 9.Navarre Cancer Registry, Navarre Public Health InstitutePamplonaSpain
  10. 10.Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive MedicineFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  11. 11.Granada Cancer Registry, Andalusian School of Public Health, Instituto de Investigación Biosanitaria ibs.GRANADAHospitales Universitarios de Granada/Universidad de GranadaGranadaSpain

Personalised recommendations